Literature DB >> 12032274

Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics.

Reinhold Feldmann1, Jonas Denecke, Michael Pietsch, Michael Grenzebach, Josef Weglage.   

Abstract

Neuropsychologic studies have shown that even phenylketonuric patients treated early suffer from phenylalanine-related deficits in all age periods, from childhood to adulthood. This study was performed to determine whether phenylketonuric children show specific frontal lobe-dependent deficits when compared with diabetic patients. The comparative study included 42 phenylketonuric patients, 10 to 18 y of age [mean 14.7 (years, months), SD 2.9], and 42 diabetic patients matched for sex, age, and socioeconomic status. Patients were assessed for intelligence quotient (Culture Fair Intelligence Test), information processing (Wisconsin Card Sorting Test, Trail-Making Test), and selective (Stroop task) as well as sustained attention (Test d-2). Phenylketonuric patients had significantly poorer results than the diabetic patients. Within all tests, however, this was due to reduced performance speed, not to deficits in specific functions. Patients did not show deficits in insight and learning. The selection abilities and the sustained attention of the phenylketonuric patients were not impaired. Performance speed and blood phenylalanine levels were negatively correlated. Elevated phenylalanine levels may cause an imbalance in neurotransmitter metabolism. However, this seems to refer to a global neurotoxic effect rather than to specific effects on the dopaminergic system, which would affect specifically the activation of the frontal lobes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032274     DOI: 10.1203/00006450-200206000-00017

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review.

Authors:  V L Brumm; C Azen; R A Moats; A M Stern; C Broomand; M D Nelson; R Koch
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

3.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

4.  Diffusion tensor images in children with early-treated, chronic, malignant phenylketonuric: correlation with intelligence assessment.

Authors:  Steven Shinn-Forng Peng; Wen-Yih Isaac Tseng; Yin-Hsiu Chien; Wuh-Liang Hwu; Hon-Man Liu
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

5.  Executive dysfunction in treated phenylketonuric patients.

Authors:  Bahare Azadi; Arshia Seddigh; Mehdi Tehrani-Doost; Javad Alaghband-Rad; Mahmoud Reza Ashrafi
Journal:  Eur Child Adolesc Psychiatry       Date:  2009-02-16       Impact factor: 4.785

6.  Executive function impairment in early-treated PKU subjects with normal mental development.

Authors:  V Leuzzi; M Pansini; E Sechi; F Chiarotti; Cl Carducci; G Levi; I Antonozzi
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.